MCL1 and acute myeloid leukemia: Co-targeting BCL-2 and MCL1 was also efficacious (LC50 < 100 nM) in a subset of primary AML samples resistant to the anthracycline drug idarubicin (LC50 > 1 μM; Fig. 1a, b).